Heart Test Laboratories, Inc. (HSCS)

NASDAQ: HSCS · IEX Real-Time Price · USD
1.75
-0.07 (-3.84%)
Jul 5, 2022 4:00 PM EDT - Market closed

Company Description

Heart Test Laboratories is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness.

Our objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging.

The MyoVista also provides conventional ECG information in the same test. Our business model, which involves the use of the MyoVista device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required for every test performed.

We previously submitted an FDA De Novo classification request in December 2019. Based on feedback and communications with the FDA during 2020, we have been making modifications to our device and are partially through a new, pivotal clinical validation study and the device testing and development necessary for a revised FDA De Novo submission, which we expect to take place later in the current fiscal year ending April 30, 2023.

Heart Test Laboratories, Inc.
Country United States
Founded 2007
IPO Date Jun 15, 2022
Industry Medical Devices
Sector Health Care
Employees 13
CEO Andrew Simpson

Contact Details

Address:
550 Reserve St, Suite 360
Southlake, TX 76092
United States
Phone 682-237-7781
Website heartsciences.com

Stock Details

Ticker Symbol HSCS
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency US Dollars
IPO Price $4.25
CIK Code 1468492
ISIN Number US42254E1047
SIC Code 3842

Key Executives

Name Position
Andrew Simpson Chief Executive Officer, President and Chairman of Directors
Mark T. Hilz Chief Operating Officer, Secretary and Director
Danielle Watson Chief Financial Officer and Treasurer

Latest SEC Filings

Date Type Title
Jun 23, 2022 8-K Current report
Jun 17, 2022 424B4 Prospectus [Rule 424(b)(4)]
Jun 15, 2022 8-K/A Current report
Jun 15, 2022 8-K Current report
Jun 15, 2022 EFFECT Notice of Effectiveness
Jun 14, 2022 CERT Certification by an exchange approving securities for listing
Jun 14, 2022 8-A12B Registration of securities [Section 12(b)]
Jun 13, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jun 10, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jun 6, 2022 FWP Filing under Securities Act Rules 163/433 of free writing prospectuses